Denali Therapeutics Inc (DNLI) - Net Assets
Based on the latest financial reports, Denali Therapeutics Inc (DNLI) has net assets worth $926.10 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.27 Billion) and total liabilities ($339.93 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check DNLI intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $926.10 Million |
| % of Total Assets | 73.15% |
| Annual Growth Rate | N/A |
| 5-Year Change | 5.35% |
| 10-Year Change | 298.3% |
| Growth Volatility | 65.22 |
Denali Therapeutics Inc - Net Assets Trend (2015–2025)
This chart illustrates how Denali Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See Denali Therapeutics Inc (DNLI) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Denali Therapeutics Inc (2015–2025)
The table below shows the annual net assets of Denali Therapeutics Inc from 2015 to 2025. For live valuation and market cap data, see market cap of Denali Therapeutics Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.01 Billion | -17.56% |
| 2024-12-31 | $1.23 Billion | +19.28% |
| 2023-12-31 | $1.03 Billion | -1.10% |
| 2022-12-31 | $1.04 Billion | +8.33% |
| 2021-12-31 | $962.29 Million | -16.36% |
| 2020-12-31 | $1.15 Billion | +191.35% |
| 2019-12-31 | $394.89 Million | -27.79% |
| 2018-12-31 | $546.85 Million | +17.40% |
| 2017-12-31 | $465.80 Million | +83.01% |
| 2016-12-31 | $254.52 Million | +1727.98% |
| 2015-12-31 | $-15.63 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Denali Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 203466400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.89 Million | 0.19% |
| Other Comprehensive Income | $682.00K | 0.07% |
| Other Components | $3.06 Billion | 302.11% |
| Total Equity | $1.01 Billion | 100.00% |
Denali Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Denali Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Anhui Great Wall Military Industry Co Ltd
SHG:601606
|
$3.30 Billion |
|
GZ Port
SHG:601228
|
$3.30 Billion |
|
Beijing Sinnet Technology Co Ltd
SHE:300383
|
$3.30 Billion |
|
New Hope Corporation Ltd
AU:NHC
|
$3.30 Billion |
|
Aneka Tambang (Persero) TBK (PT)
AU:ATM
|
$3.30 Billion |
|
Huhtamaki Oyj
HE:HUH1V
|
$3.30 Billion |
|
NBCC (India) Limited
NSE:NBCC
|
$3.29 Billion |
|
Shenzhen Yan Tian Port Holdings Co Ltd
SHE:000088
|
$3.29 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Denali Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,229,684,000 to 1,013,761,000, a change of -215,923,000 (-17.6%).
- Net loss of 512,540,000 reduced equity.
- New share issuances of 189,249,000 increased equity.
- Other comprehensive income decreased equity by 1,338,000.
- Other factors increased equity by 108,706,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-512.54 Million | -50.56% |
| Share Issuances | $189.25 Million | +18.67% |
| Other Comprehensive Income | $-1.34 Million | -0.13% |
| Other Changes | $108.71 Million | +10.72% |
| Total Change | $- | -17.56% |
Book Value vs Market Value Analysis
This analysis compares Denali Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.07x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-5.20 | $23.49 | x |
| 2016-12-31 | $39.62 | $23.49 | x |
| 2017-12-31 | $31.13 | $23.49 | x |
| 2018-12-31 | $5.90 | $23.49 | x |
| 2019-12-31 | $4.13 | $23.49 | x |
| 2020-12-31 | $10.21 | $23.49 | x |
| 2021-12-31 | $7.92 | $23.49 | x |
| 2022-12-31 | $8.30 | $23.49 | x |
| 2023-12-31 | $7.50 | $23.49 | x |
| 2024-12-31 | $7.48 | $23.49 | x |
| 2025-12-31 | $5.78 | $23.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Denali Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -50.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.13x
- Recent ROE (-50.56%) is below the historical average (-24.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.22 Million |
| 2016 | -34.05% | 0.00% | 0.00x | 1.07x | $-112.10 Million |
| 2017 | -18.93% | 0.00% | 0.00x | 1.04x | $-134.76 Million |
| 2018 | -6.63% | -28.06% | 0.20x | 1.21x | $-90.92 Million |
| 2019 | -50.04% | -740.74% | 0.05x | 1.40x | $-237.10 Million |
| 2020 | 6.18% | 21.19% | 0.21x | 1.39x | $-43.92 Million |
| 2021 | -30.20% | -597.15% | 0.03x | 1.46x | $-386.81 Million |
| 2022 | -31.27% | -300.56% | 0.07x | 1.40x | $-430.23 Million |
| 2023 | -14.09% | -43.94% | 0.29x | 1.12x | $-248.32 Million |
| 2024 | -34.38% | 0.00% | 0.00x | 1.12x | $-545.74 Million |
| 2025 | -50.56% | 0.00% | 0.00x | 1.13x | $-613.92 Million |
Industry Comparison
This section compares Denali Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Denali Therapeutics Inc (DNLI) | $926.10 Million | 0.00% | 0.37x | $3.30 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 pr… Read more